Targets › CDK19
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.
Component of the Mediator complex, a transcriptional coactivator required for regulated expression of nearly all RNA polymerase II-dependent genes. Acts as a molecular bridge between gene-specific regulatory proteins and the basal RNA polymerase II transcription machinery. (UniProt, Q9BWU1)
Open in Phaseline: the race on CDK19, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ryvu Therapeutics | RVU120 CDK8 and CDK19 inhibitor | CDK8, CDK19 | Phase 2 | Acute Myeloid Leukemia | Aug 2027 |
Acute Myeloid Leukemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.